STOCK TITAN
  1. Home
  2. News
  3. PRLD

Prelude Therapeutics Inc - PRLD STOCK NEWS

Welcome to our dedicated news page for Prelude Therapeutics (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prelude Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prelude Therapeutics's position in the market.

News
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Rhea-AI Summary
Prelude Therapeutics (Nasdaq: PRLD) presents new preclinical data at AACR Annual Meeting showcasing promising results for its SMARCA2 degrader, CDK9 inhibitor, and CDK4/6 inhibitor. The SMARCA2 degrader, PRT7732, exhibits high potency and selectivity, with plans for Phase 1 trials in 2024. The CDK9 inhibitor, PRT2527, shows efficacy in hematological models and is in Phase 1 trials. The CDK4/6 inhibitor, PRT3645, displays synergies in breast cancer, CRC, and NSCLC models, hinting at improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
-
News
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Rhea-AI Summary
Prelude Therapeutics Incorporated announces the acceptance of three posters with preclinical data on its highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor, and next-generation CDK4/6 inhibitor for presentation at the AACR Annual Meeting 2024. The Company's Chief Scientific Officer, Peggy Scherle, looks forward to sharing data on the preclinical characterization of PRT7732, the lead oral SMARCA2 degrader, which is set to enter Phase 1 clinical development in the second half of the year. Additionally, preclinical data for the highly selective CDK9 inhibitor, PRT2527, and the next-generation CDK4/6 inhibitor, PRT3645, will be presented, highlighting their potential therapeutic value in various cancer types. The Company will also host a live webcast to discuss the role of SMARCA in cancer and its clinical relevance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
News
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Rhea-AI Summary
Prelude Therapeutics Incorporated (Nasdaq: PRLD) will participate in the Barclays Global Healthcare Conference. The CEO and Chief Medical Officer will be part of a fireside chat on March 13, 2024. The event will be live webcasted and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
conferences
News
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
Rhea-AI Summary
Prelude Therapeutics Incorporated (PRLD) reports financial results for 2023 and outlines key objectives for 2024. The company focuses on first-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor. A partnership with AbCellera aims to develop precision ADCs. The company has a cash runway into 2026 with $232.9 million in cash. Clinical milestones for 2024 include proof-of-concept data for SMARCA2 degrader and CDK9 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.05%
Tags
earnings
-
News
Prelude Therapeutics Announces $25 Million Private Placement
Rhea-AI Summary
Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a private placement to raise approximately $25 million in gross proceeds, which will be used to fund the advancement of its SMARCA2 portfolio, for working capital, and general corporate purposes. The additional funding is expected to sustain the company's operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Rhea-AI Summary
Prelude Therapeutics announces the prioritization of its SMARCA2 degrader and CDK9 inhibitor programs for continued clinical development. The company also enters a partnership with AbCellera to develop precision ADCs. Prelude has a cash runway into 2026 with $230.5 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.82%
Tags
partnership earnings
News
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Rhea-AI Summary
Prelude Therapeutics and AbCellera have announced a multi-year, multi-program partnership to discover, develop, and commercialize novel oncology medicines. The collaboration will focus on up to five programs, with the first program targeting a SMARCA degrader. Prelude will lead clinical development and global commercialization, while AbCellera will lead manufacturing activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.82%
Tags
partnership
-
News
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
Rhea-AI Summary
Prelude Therapeutics to participate in three upcoming healthcare investment conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
conferences
-
News
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Prelude Therapeutics reports Q2 2023 financial results and pipeline updates. Recent financing extends cash runway into 2026. Lead programs PRT2527 and PRT1419 show promising clinical safety profiles and target inhibition. PRT3645 and PRT3789 progressing well in Phase 1. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $255.0 million. R&D expense increased to $25.0 million. Net loss for Q2 2023 was $30.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
earnings
News
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
conferences
Stock PRLD logo
Prelude Therapeutics Inc

Nasdaq:PRLD

PRLD Rankings

#3701 Ranked by Market Cap
#5192 Ranked by Stock Gains
N/A Ranked by Dividends

PRLD Stock Data

308.65M
13.62M
6.93%
73.74%
1.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Wilmington

About PRLD

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.